In this study a total of 548 known positive and negative samples were tested. 59% of samples tested for CMV were positive and 35% of samples tested for Syphilis were positive. The results were derived using microarrays manufactured in Quotient’s validated, high-volume manufacturing facility and run on field trial ready instruments. The process validation studies represent the final step prior to commencing formal V&V studies for the MosaiQ SDS Microarray. MosaiQ IH Microarray - Update: Underyling blood grouping assays for MosaiQ continue to perform to expectations. All assays required for the MosaiQ IH II Microarray (incorporating the extended antigen typing panel for donor testing) have completed development and transfer of these assays to manufacturing has commenced. After an investigation late last year into the physical properties of the printed microarrays, specifically the preservative layer, it was decided to modify the manufacturing process for MosaiQ microarrays. The modification is expected to further improve the performance and robustness of MosaiQ, particularly as it relates to the antigen typing assays.